The clinical development of a 5α-reductase inhibitor, finasteride
November 1990
in “The Journal of Steroid Biochemistry and Molecular Biology”
TLDR Finasteride effectively treats BPH, but needs more trials to understand potential.
The paper discusses the clinical development of finasteride, a 5α-reductase inhibitor used to treat benign prostatic hyperplasia (BPH). Studies showed that finasteride significantly decreased the level of circulating dihydrotestosterone (DHT) in normal volunteers and suppressed intraprostatic DHT levels in BPH patients. Prostate volume decreased by a mean of 18% after 12 weeks of treatment and continued to shrink throughout the initial 6 months of therapy. The maximum urinary flow rate increased by approximately 3 ml/s in the drug-treated group. The paper concludes that finasteride is effective in treating BPH, but more extensive clinical trials are needed to fully understand its therapeutic potential.
View this study on sciencedirect.com →
Related
research A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia
research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Finasteride effectively treats BPH but may increase sexual dysfunction risk.
research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.
Finasteride doesn't affect hormone levels in normal men.
research The clinical development of a 5α-reductase inhibitor, finasteride
Finasteride effectively treats BPH, but needs more trials to understand potential.